RE: Has this still got legs?9 Oct 2025 08:29
Yes, is the answer, Aptamer certainly does have legs to go a lot further. With another meaningful cash earning deal under its belt, Aptamers cash runway has been extended well into next year, giving plenty of time for the Astrazeneca project to come to a head and pay off big time. This quote from Ian Lyall at ProActive says it all, 'Alongside the new contract, the group reported a strong start to its financial year, securing an additional £665,000 in new agreements, including £315,000 of smaller deals and project extensions. Together with contracts carried over from last year, this gives the York-based firm about £1.03 million in total contract value for the current period, with nine months of the year remaining. Aptamer said its sales pipeline remains “robust” at £3.4 million in fee-for-service opportunities, suggesting further deal flow in the months ahead.'